> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Taiho Reports Unfavorable DMD Drug Data
- URL: https://www.fdaweb.com/taiho-reports-unfavorable-dmd-drug-data/
- Published: 2025-07-08T12:00:00.000Z
- Updated: 2026-09-14T15:15:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159469

Taiho Pharmaceutical is reporting disappointing data from its Phase 3 extension study of TAS-205 (pizuglanstat) in patients with Duchenne muscular dystrophy (DMD) (REACH-DMD) that showed no significant difference in the mean change from baseline to 52 weeks in the time to rise from the floor, which was the primary endpoint in the ambulatory cohort of the study. The ambulatory cohort of the study was conducted in Japan in male DMD patients aged five years and older, according to the company. Detailed results will be presented at an appropriate upcoming academic conference, it says.

TAS-205 is described as a selective hematopoietic prostaglandin D synthase (HPGDS) inhibitor discovered by Taiho. It is being developed as a DMD treatment for use regardless of the dystrophin gene mutation type. It is intended to control the decline in motor function in DMD patients by inhibiting HPGDS, which exacerbates the inflammatory response in patients’ muscles, according to the company.